Ekso Bionics Holdings, Inc. (EKSO)
Stock Price:
$7.35 USD
0.12 (1.66%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
55.79M |
| Revenue (ttm) |
11.77M |
| Net Income (ttm) |
-8.12M |
| Shares Out |
7.59M |
| EPS (ttm) |
-1.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$7.35 |
| Previous Close |
$7.23 |
| Change ($) |
0.12 |
| Change (%) |
1.66% |
| Day's Open |
7.16 |
| Day's Range |
7.16 - 7.94 |
| Day's Volume |
1,085,622 |
| 52-Week Range |
2.25 - 19.65 |
More Stats
| Market Cap |
55.79M |
| Enterprise Value |
50.48M |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
7.59M |
| Float |
4.28M |
| EPS (basic) |
-1.64 |
| EPS (diluted) |
-1.59 |
| FCF / Share |
-2.13 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
294,166 |
| Short Ratio |
2.02 |
| Short % of Float |
5.49% |
| Beta |
1.94 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.74 |
| PB Ratio |
5.20 |
| Revenue |
11.77M |
| Operating Income |
-16.51M |
| Net Income |
-8.12M |
| Free Cash Flow |
-12.37M |
| Net Cash |
5.32M |
| Net Cash / Share |
0.70 |
| Gross Margin |
57.47% |
| Operating Margin |
-140.28% |
| Profit Margin |
-69.00% |
| FCF Margin |
-105.11% |
| ROA |
-54.58% |
| ROE |
-166.26% |
| ROIC |
-116.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.50*
(70.07% upside)
Low
12.0
Current: 7.35
High
13.0
Target: 12.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 13.92 | 11.33 | 7.35 | 14.22 | 8.66 | 5.33 | 3.30 | 2.71 |
| Revenue Growth | 22.81% | 54.11% | -48.29% | 64.2% | 62.59% | 61.33% | 22.03% | - |
| Gross Profit | 6.76 | 4.31 | 2.07 | 2.95 | 1.18 | 1.56 | 0.59 | 0.37 |
| Operating Income | -16.64 | -27.03 | -31.94 | -27.78 | -21.56 | -16.79 | -10.29 | -14.24 |
| Net Income | -12.13 | -26.99 | -29.12 | -23.47 | -19.59 | -33.77 | -11.89 | -15.04 |
| Shares Outstanding | 4.79 | 4.08 | 2.37 | 1.21 | 0.97 | 0.75 | 0.20 | 0.19 |
| Earnings Per Share | -2.55 | -6.60 | -12.30 | -30.75 | -27.45 | -45.30 | -59.85 | -78.74 |
| Operating Cash Flow | -15.77 | -22.17 | -31.23 | -25.00 | -18.27 | -15.01 | -9.06 | -12.66 |
| Capital Expenditures | -0.06 | -0.13 | -0.46 | -1.10 | -1.49 | -1.49 | -0.38 | -0.83 |
| Free Cash Flow | -15.83 | -22.30 | -31.68 | -26.09 | -19.76 | -16.49 | -9.44 | -13.49 |
| Cash & Equivalents | 10.87 | 7.66 | 27.81 | 16.85 | 19.55 | 25.19 | 0.81 | 1.74 |
| Total Debt | 3.47 | 4.98 | 6.97 | 6.79 | 0.08 | 0.04 | 7.57 | 7.69 |
| Net Cash / Debt | 7.41 | 2.67 | 20.84 | 10.06 | 19.47 | 25.15 | -6.76 | -5.96 |
| Assets | 21.92 | 17.66 | 37.99 | 24.43 | 32.20 | 33.47 | 6.58 | 6.21 |
| Liabilities | 15.12 | 14.93 | 16.60 | 17.89 | 23.39 | 10.67 | 15.63 | 14.62 |
| Book Value | 6.80 | 2.73 | 21.39 | 6.53 | 8.81 | 22.80 | -36.37 | -25.09 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Ekso Bionics Holdings, Inc. |
| Country |
United States |
| Employees |
67 |
| CEO |
Jack Peurach |
Stock Information
| Ticker Symbol |
EKSO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NASDAQ: EKSO |
Description
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke. The company's Ekso device is primarily used in a hospital and rehabilitation setting. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California.